Magnesium L-threonate has stronger human clinical evidence for direct brain benefits than magnesium glycinate, primarily because it crosses the blood-brain barrier more efficiently. However, no head-to-head trial directly compares the two, and both forms show promise through different pathways—making the choice depend on your age, health profile, and specific brain-health goals.
Magnesium L-threonate is a magnesium salt bound to threonate, an oxidized vitamin C metabolite, designed to penetrate the brain's protective barrier. Magnesium glycinate, by contrast, is magnesium bound to the amino acid glycine—highly absorbable in the gut but less efficient at reaching brain tissue. This difference in how each form acts explains why their evidence bases diverge and why understanding what each trial measured matters for your decision.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Each Form Enters (or Doesn't) the Brain
- Human Evidence for Magnesium L-Threonate
- Human Evidence for Magnesium Glycinate
- The Missing Link—Why No Direct Comparison
- Who Might Benefit From Each Form—And Key Limitations
How Each Form Enters (or Doesn't) the Brain
Magnesium L-threonate's threonate ligand binds to glucose transporters that the brain uses to absorb fuel, allowing magnesium to cross the blood-brain barrier—a gateway normally impermeable to most magnesium salts. This hitchhiking mechanism is the core reason researchers hypothesized it would work better for cognition than standard forms.
Magnesium glycinate, while highly bioavailable when swallowed due to its chelated glycine binding, reaches systemic circulation rather than brain tissue directly. It may support brain health indirectly through glycine itself, a neurotransmitter with calming properties. The two supplements operate on fundamentally different principles: one targets direct magnesium delivery to the brain; the other delivers systemic calm and indirect CNS benefit.
Human Evidence for Magnesium L-Threonate
A 2026 double-blind, placebo-controlled trial with 100 participants aged 18–45 found that 6 weeks of 2g daily magnesium L-threonate reduced brain cognitive age by approximately 7.5 years compared to placebo. The trial measured this via NIH Total Cognition Composite scores, with the largest improvements in working and episodic memory (p=0.043). All participants had poor sleep at baseline, so results may not generalize to people with normal sleep.
The same trial also reported faster reaction times and improved sleep quality measures in the L-threonate group. This is the most rigorous human evidence available for either magnesium form—rigorous meaning blinded, placebo-controlled, and recently published. The downside: the 6-week window is short for assessing long-term safety, and no older adults were enrolled.
Human Evidence for Magnesium Glycinate
Glycinate's evidence base is smaller and older. A secondary analysis found 9.1% improvement in Montreal Cognitive Assessment (MoCA) scores among adults aged 65+ after 12 weeks of magnesium glycinate. The improvement is measurable but modest compared to the 7.5-year cognitive age reduction in the younger L-threonate group.
Critically, the glycinate study acknowledged a lower-quality design than the L-threonate trial. This doesn't mean the result is wrong—9.1% is still a real cognitive boost—but it means less confidence in the effect size or reproducibility. Glycinate's inability to cross the blood-brain barrier efficiently suggests any cognitive benefit would come from indirect pathways, not direct brain magnesium delivery.
The Missing Link—Why No Direct Comparison
No direct head-to-head human trials comparing magnesium L-threonate and glycinate for brain health exist. The L-threonate trial recruited younger, sleep-deprived adults; the glycinate evidence comes from older adults. They measured different outcomes, used different protocols, and recruited different populations—making any claim that one is "better" speculative rather than evidence-based.
This gap is critical for readers seeking clarity. You cannot look to human trials and say "L-threonate wins" or "glycinate is sufficient"—the trials simply do not allow that comparison. You're weighing L-threonate's stronger mechanistic rationale and evidence in a younger population against glycinate's weaker evidence in an older one. Neither choice rests on head-to-head proof.
Who Might Benefit From Each Form—And Key Limitations
If you're younger (18–45) with cognitive concerns and poor sleep, L-threonate has specific evidence in your demographic. If you're older (65+), the glycinate evidence—though weaker—at least targeted your age group. Both studies leave middle-aged adults and anyone with existing dementia diagnosis unsupported by human trial data.
Important caveats: both trials are recent and small (100 and unspecified n for glycinate, respectively). L-threonate's 7.5-year cognitive-age reduction is striking but based on 6 weeks—too short to predict long-term safety or whether benefits persist after stopping. Neither form is FDA-approved for dementia or cognitive decline, and both should be discussed with a provider, especially if you take medications or have kidney disease, since magnesium supplementation carries risks in renal impairment. Neither replaces sleep, exercise, and cognitive engagement—the evidence-backed foundations of brain health at any age.
